Arcus Biosciences RCUS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $201M-9.5% | $222M-6.7% | $238M-4.0% | $248M+29.2% | $192M+28.0% | ||
| $621M-18.2% | $759M+28.0% | $593M-10.6% | $663M-17.6% | $805M-2.8% | ||
| $844M-16.2% | $1.01B+17.5% | $857M-9.4% | $946M-8.2% | $1.03B+1.5% | ||
| $38M-5.0% | $40M-4.8% | $42M-4.5% | $44M-4.3% | $46M-2.1% | ||
| $997M-12.5% | $1.14B+16.9% | $974M-9.4% | $1.08B-7.0% | $1.16B+0.5% | ||
| $39M-7.1% | $42M0.0% | $42M+44.8% | $29M+31.8% | $22M+22.2% | ||
| $34M-2.9% | $35M-32.7% | $52M-26.8% | $71M-1.4% | $72M-15.3% | ||
| $209M-9.5% | $231M-1.7% | $235M+11.9% | $210M+9.4% | $192M-15.0% | ||
| $100M+1.0% | $99M+1.0% | $98M+1.0% | $97M+102% | $48M0.0% | ||
| 400M0.0% | 400M0.0% | 400M0.0% | 400M0.0% | 400M-75.3% | ||
| -$1.61B-8.6% | -$1.49B-7.7% | -$1.38B-10.9% | -$1.24B0.0% | -$1.24B-9.9% | ||
| $524M-17.0% | $631M+44.7% | $436M-20.6% | $549M+3.4% | $531M+9.5% | ||
| $997M-12.5% | $1.14B+16.9% | $974M-9.4% | $1.08B-7.0% | $1.16B+0.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Arcus Biosciences cover its short-term obligations?
- Its current ratio is 4.04 — current assets exceed current liabilities.
- Where does Arcus Biosciences's balance sheet data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.